Back
Compare AU
Compare HVST vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Australian Dividend Harvester Active ETF (HVST) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HVST | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 76 | 73 |
Median incremental investment | $990.50 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,471.74 | $2,093.32 |
Average age group | > 35 | > 35 |
Key Summary
HVST | DRUG | |
|---|---|---|
Strategy | HVST.AX was created on 2014-10-29 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. HVST.AX aims to provide exposure to large-cap Australian shares, along with the potential for franked income that is at least 1.5x the yield of the Australian broad sharemarket on an annual basis. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | SPI 200 FUTURES DEC26 (0 %) BETASHARES AUSTRALIA 200 ETF (24.60 %) BHP GROUP LTD (9.54 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (50.68 %) Financials (12.82 %) Health Care (6.32 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | Australia (96.35 %) United States (2.15 %) United Kingdom of Great Britain and Northern Ireland (0.84 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.65 % | 0.57 % |
Key Summary
HVST | DRUG | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.65 % | 0.57 % |
Price | $12.97 | $8.83 |
Size | $275.962 million | $173.548 million |
10Y return | -36.11 % | 82.44 % |
Annual distribution yield (5Y) | 5.28 % | 1.82 % |
Market | ASX | ASX |
First listed date | 03/11/2014 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HVST | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 76 | 73 |
Median incremental investment | $990.50 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,471.74 | $2,093.32 |
Average age group | > 35 | > 35 |
Pros and Cons
HVST | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HVST | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |